Financials
Financial year 2025
JSMAL BioTech Consulting from Esneux, company number BE0641867905, closed financial year 2025 with a result of € 305,265 after tax. For that financial year JSMAL BioTech Consulting recorded a gross margin of € 460,482 and equity of € 443,697. Compared with financial year 2024, the result moved from € 213,261 to € 305,265. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 443,697
▲ 221% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 305,265
▲ 43% vs 2024
Profit after tax over the fiscal year.
€ 264,990
▲ € 222,690 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 424,797.
People and assets in 2025
€ 4,480
▼ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,022
▼ 56% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 97,829
▲ 136% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 296,634 | € 368,027 | € 284,818 | € 460,482 | ▲ 62% |
| Profit after taxes | € 205,685 | € 276,872 | € 213,261 | € 305,265 | ▲ 43% |
| Equity | € 241,203 | € 139,075 | € 138,432 | € 443,697 | ▲ 221% |
| Total debts | € 34,872 | € 410,824 | € 262,255 | € 100,851 | ▼ 62% |
| Cash | € 9,178 | € 272,792 | € 42,300 | € 264,990 | ▲ € 222,690 |
| Retained profit | € 222,303 | € 120,175 | € 119,532 | € 424,797 | ▲ 255% |
| Dividend | € 200,000 | € 379,000 | € 213,904 | € 0 | ▼ 100% |
| Balance sheet total | € 276,075 | € 549,900 | € 400,687 | € 544,548 | ▲ 36% |
Key figures of JSMAL BioTech Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JSMAL BioTech Consulting?
What happened at JSMAL BioTech Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 305,265 (▲ 43% vs 2024). Source: NBB ↗
- New establishment in Esneux. KBO
- Start of the company according to the CBE. KBO
In short
From € 205,685 profit in 2022 to € 305,265 profit in 2025.
Paid € 371,423 in corporate taxes since 2022.
Best year ever: 2025, with € 305,265 profit.
Paid out € 792,904 in dividends to the owners in total.
Management
Behind JSMAL BioTech Consulting is Jean Smal. It owns 100% of Conveyxo itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Chemin des Thiers 12
4130 Esneux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0641.867.905
- VAT number
- BE 0641.867.905
- Registered office
- Chemin des Thiers 12, 4130 Esneux
- Names & denominations
- JSMAL BioTech Consulting · JSBTC
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 October 2015
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts